Clinical trials: Hearth Failure With Reduced Ejection Fraction (HFrEF)
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Hearth Failure With Reduced Ejection Fraction (HFrEF), Cardiac Resynchronisation Therapy (CRT)
THE RELATIONSHIP BETWEEN CARDIAC RESYNCHRONİZATION THERAPY RESPONSE IN HEART FAILURE PATIENTS AND YKL-40 LEVELS
Patients diagnosed with heart failure at our clinic who routinely undergo CRT implantation will be included in the study. This decision is independent of the study.
- Conditions
- Hearth Failure With Reduced Ejection Fraction (HFrEF), Cardiac Resynchronisation Therapy (CRT), Left Branch Bundle Block
- Trial name
- NCT07469137
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people
- Sponsor
- Trakya University
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Medication Training Via Ignite Based on Roy Model in Heart Failure: Medication Adherence and Symptom Management
The goal of this clinical trial is to learn if a structured medication training program can help people with heart failure better manage their condition.
- Trial name
- NCT07538596
- Testing
- Ignite-Based Medication Management Training
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Saglik Bilimleri Universitesi